anthropic.com
|
ksl
|
|
Anthropic appointed Vas Narasimhan, the sitting CEO of Novartis, to its board of directors. The pick came through the Long-Term Benefit Trust, and with his addition, Trust-appointed directors now hold a board majority – a quiet but significant governance milestone. Narasimhan’s background is in pharmaceutical R&D, not tech, which makes the choice pointed. Anthropic seems to be stacking its oversight layer with people experienced in navigating regulated, high-stakes product launches rather than the usual Silicon Valley board profiles. OpenAI, Google DeepMind, and others have faced growing scrutiny over governance structures, and Anthropic is clearly trying to get ahead of that conversation.
